ZG16B

Across TCGA pan-cancer cohorts, ZG16B mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated ZG16B data layer compared with 22 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ZG16B mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ZG16B expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

LUAD and HNSC are the cancer types where ZG16B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	II,III,IV	0.161	0.783	.010	4	view →
HNSC	DFS	Quartile	III,IV	0.947	0.333	.024	3	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

ZG16B–LUAD (DFS)

Open the LUAD breakdown →